

BOARD OF PHARMACY

Professional & Vocational Licensing Division
Department of Commerce and Consumer Affairs
State of Hawaii

MINUTES OF MEETING

Date: Thursday, May 17, 2018

Time: 9:00 a.m.

Place: King Kalakaua Building
335 Merchant Street
Queen Liliuokalani Conference Room First Floor
Honolulu, Hawaii 96813

Members Present: Kerri Okamura, RPh, Chair, Pharmacist
Julie Takishima-Lacasa, PhD, Vice Chair, Public
Marcella Chock, PharmD., Pharmacist
Mary Jo Keefe, RPh, Pharmacist
Carolyn Ma, PharmD., BCOP, Pharmacist
Ronald Weinberg, Public

Members Excused: Kenneth VandenBussche, RPh, BCACP, Pharmacist

Staff Present: Lee Ann Teshima, Executive Officer ("EO")
Nohelani Jackson, Secretary

Guests: Alanna Isobe, Safeway
Paul Smith, Walgreens
Ashok Kota, Foodland
Stacy Pi, Kaiser Permanente
Matt Tsujimura, SanHI Govt Strategies
Davis Chang
Wayne Yoshioka, Hawaii Public Radio
Jonathan Ching, Kaiser Permanente
Catalina Cross, Times
Reece Uyeno, Pharmicare

Call to Order: The agenda for this meeting was filed with the Office of the Lieutenant Governor, as required by section 92-7(b), Hawaii Revised Statutes ("HRS").

There being a quorum present, the Chair called the meeting to order at 9:00 a.m.

Chair's Report: **Announcements and Introductions**

The Chair excused Mr. VandenBussche and asked the audience to introduce themselves.

Approval of the Previous Minutes –April 19, 2018 Meeting

The Chair called for a motion in regards to the minutes of the April 19, 2018 meeting.

There being no amendments, upon a motion by Mr. Weinberg, seconded by Dr. Ma, it was voted on and unanimously carried to approve the minutes for the April 19, 2018 meeting as circulated.

Executive Officer's **Conferences/Seminars/Meetings**
Report:

NABP Annual Meeting, May 5-8, 2018

Ms. Keefe reported that the following topics were discussed at the annual meeting:

- The assembly passed the following resolutions:
 1. Sharing the Model Act wording addressing the implementation and regulation of the use of technology in pharmacy with state legislators and regulatory authorities;
 2. Encourage USP and other stakeholders to develop educational materials concerning chapter 800 to be given to patients and caregivers;
 3. Work with DEA, CMS, and electronic experts to examine the feasibility of mandating that all prescriptions be transmitted electronically (New York already requires this);
 4. Develop an interdisciplinary task force to explore the transition from a strictly prescriptive rule-based regulations pharmacy act to a model that includes a standard of care process, and discuss the necessary tools for boards of pharmacy to make this transition;
- Breakout sessions and “hot” topics included the following:
 1. Regulating medical marijuana, pharmacy should be “involved”, however medical marijuana should be medicine;
 2. Medication assisted treatment in combating the opioid epidemic,
 3. Transitioning pharmacy regulation to standards of care;
 4. Interstate licensing of pharmacists;
 5. Getting rid of PICs;
 6. Registering/licensing techs and the portability of those licenses across state lines;
 7. USP further clarified that 795, 797, and 800 will all be aligned and 800 will go into effect December 2019;
 8. Electronic transmission of all prescriptions.

NABP/AACP Districts VI, VII & VII (Annual Meeting, October 14, 17, 2018, Kansas City, Missouri)

The EO announced that the NABP/AACP district meeting will be held in October and if anyone was interested to let her know as soon as possible.

2018 Legislation

The EO reported on the status of the following bills:

SB 2247, SD1, HD2, CD1 Relating to Opioid Antagonists – Authorizes pharmacists to prescribe, dispense, and provide related education on opioid antagonists to individuals at risk of opioid overdose and to family members and caregivers of individuals at risk of opioid overdose without the need for a written, approved collaborative agreement; subject to certain conditions. (CD1) Enrolled to Governor on 5/3/2018.

HB 2145, HD1, SD1, CD1 Relating to Medication Synchronization - Allows the synchronization of plan participants' medications. Requires plans, policies, contracts, or agreements that are offered by health insurers, mutual benefit societies, and health maintenance organizations and provide prescription drug benefits, to apply prorated daily cost-sharing rates for prescriptions dispensed by network pharmacies for less than a thirty-day supply. (HB2145 CD1) Transmitted to Governor on 4/30/2018

SB 2298, SD2, HD3, CD1 Relating to Healthcare Preceptor Tax Credits – Allows advanced practice registered nurses, pharmacists, and physicians to receive income tax credits for acting as preceptors in volunteer-based supervised clinical training rotations provided to eligible students that enable the students to obtain an eligible healthcare professional degree or certificate. Applies to taxable years beginning after 12/31/2018. (CD1) Enrolled to the Governor on 5/3/2018

SB 2774, SD1, HD1 Relating to Insurance – Updates various areas of the State's insurance laws to: adopt the NAIC's Corporate Governance Annual Disclosure Model Act beginning on 1/1/2020; allow the Department of Commerce and Consumer Affairs and the Insurance Commissioner to determine whether a request to add or change a trade name or assumed name satisfies certain requirements; clarify certain provider reimbursement requirements; adopt revisions to the Insurance Holding Company System Regulatory Act beginning on 1/1/2020; provide the Insurance Commissioner with additional regulatory authority to supervise or liquidate a captive insurer; enable the Insurance Division to create stopgap measures, until 12/31/2020, to implement the Network Adequacy Model Act; and make various housekeeping amendments to clarify existing language and avoid ambiguities. (SB2774 HD1) Was going to conference, however, House conferees were discharged on 4/27/2018.

The EO recommended that should the Board convene a working group, that the group review/discuss the possibility of submitting a bill that would address provider reimbursement requirements that was included in the insurance bill.

HB 1602, HD2, SD1, CD1 Relating to Opioids - Requires the inclusion of a label warning of the risks of addiction and death on the packaging of any opioid drug dispensed by a health care professional or pharmacist. (HB1602 CD1) Transmitted to Governor on 5/3/2018

SB3104, SD2, HD2– Relating to Pharmacy Benefit Managers - Establishes requirements for pharmacy benefit managers and maximum allowable cost, including the ability of pharmacies to receive comprehensive maximum allowable cost lists and bring complaints within the purview of the Department of Commerce and Consumer Affairs, rather than the Department of Health. Requires pharmacy benefit managers to disclose where an equivalent drug can be obtained at or below the maximum allowable cost when a maximum allowable cost is upheld on appeal. Allows contracting pharmacies to reverse and rebill claims if the pharmacy benefit manager establishes a maximum allowable cost that is denied on appeal and is required to pay the difference to the contracting pharmacies. Preserves the prohibition of a contracting pharmacy from disclosing the maximum allowable cost list and related information to any third party. (SB3104 HD1) Was going to conference, however, House conferees were discharged on 4/26/2018

HB 2739, HD1 – Relating to Health - Establishes a regulated process under which an adult resident of the State with a medically confirmed terminal disease and less than six months to live may choose to obtain a prescription for medication to end the patient's life. Imposes criminal sanctions for tampering with a patient's request for a prescription or coercing a patient to request a prescription. (HB2739 HD1) – Act 2, SLH 2018

The EO recommended that the Board should consider placing information about Act 2, SLH 2018 in the Corresponding Responsibility Guidance Document as it would pertain to controlled substances. She also recommended that the Board review states that have passed similar laws to see if any "guidance" was issued for pharmacists who had conflicting beliefs in filling such prescriptions.

HCR 145, HD1/SCR 135, SD1 - REQUESTING THE BOARD OF PHARMACY TO CONVENE A WORKING GROUP TO REVIEW THE CURRENT SCOPE OF PRACTICE, LICENSING REQUIREMENTS, AND CONTINUING EDUCATION REQUIREMENTS FOR PHARMACISTS AND CONSIDER WHETHER THE SCOPE OF PRACTICE AND CORRESPONDING LICENSING REQUIREMENTS FOR PHARMACISTS SHOULD BE ENHANCED. HCR not heard by FIN, SCR not heard by FIN after it crossed over to the House

The EO stated that since the resolutions did not pass, asked if the Board was interested in convening a working group anyway to include individuals representing the organizations listed in the resolutions as well as stakeholders who took the time to testify on the pharmacy bills.

It was the consensus of the Board to convene a working group to review the bills of the 2018 legislative session that passed or did not pass, i.e. return of drugs for disposal and discuss any initiatives for the 2019 Legislative Session.

Dr. Ma asked about SB 2646 (HD2, CD1) relating to the electronic prescription accountability system or the Hawaii Prescription Drug Monitoring Program ("PDMP") under the jurisdiction of the Department of Public Safety, Narcotics Enforcement Division.

The EO stated that she will add this to the agenda for the June Board meeting.

Revisions to Pharmacist's Corresponding Responsibility Guidance Statement - Draft

The EO reported that she is holding on to the guidance book so that when the pharmacy bills are enacted, including but not limited to the opioid antagonist and warning label, she wanted to include the information about the new laws, specifically the ones relating to controlled substances and opioids (opioid antagonist).

Pharmacists Continuing Education Audit – Report

The EO reported that she will start reviewing the submissions next week. She said she will start reviewing the CPE Monitor reports first and then review the submissions of continuing education completion certificates.

Working Conditions Survey

The Chair reported that as previously discussed by the Board, she drafted a survey of questions relating to working conditions. She stated that Oregon conducted a similar survey. The Board had discussed pharmacy “working conditions” as an attributing factor for pharmacy errors resulting in possible consumer harm and recommends that perhaps a survey be conducted to determine what the working conditions for pharmacists working in Hawaii.

The Board recommended additional questions relating to “quota requirements”, additional services, i.e. emergency contraception and an initial question on if the individual pharmacist is currently practicing in this State.

The EO reported that the May 2018 geo report indicated 1,400 pharmacists listing a Hawaii residence address.

The Board discussed the cost and how to implement the dissemination of the survey, i.e. hard copy, survey monkey, etc.

Dr. Ma said she would check on this to see if the school can provide some assistance.

The EO stated she will check with administration on the cost of mailing out a post card referring pharmacists to the survey whether it be on the Board's web page.

The EO also indicated that the information from participants of the survey should be kept confidential and that any information identifying the pharmacists or where they are employed should not be indicated, but more in general, i.e. hospital, retail, etc.

After some discussion, it was the consensus of the Board to have the EO and Dr. Ma report back on how to implement this initiative.

Correspondence: **National Association of Boards of Pharmacy (“NABP”)**

News Roundup

The Chair stated that in the April 2018 issue, the following articles were included:

- Dispensing Pharmacists in Arizona Are Now Required to Check Patient Report in PMP
- New Container Requirements for Schedule II Opioids in Arizona
- Arizona Pharmacies Must Accept Electronic Prescriptions in 2019
- Nevada Bill Revises Provisions Related to Dispensing Contraceptive Prescriptions
- North Carolina Controlled Substance Reporting System Is Now Connected to PMP InterConnect
- North Carolina Board Launches Public Service Announcement Campaign Concerning the Opioid Crisis

State Board of Pharmacy ACPE CPE Activity

The Board discussed the application for ACPE CE Activity approval. The EO reported that when she received the information about ACPE CPE Activity, she thought if the Board would consider offering an ACPE course covering Laws and Rules Updates.

After further discussion, the Board asked the EO to find out more information on the cost and other information should they decide to offer an ACPE CE course.

White and Brown Bagging Emerging Practices, Emerging Regulation

The Chair reported that the NABP staff executed study by reviewing NABPLaw and other sources to determine how state boards of pharmacy have defined and regulated the practices and develop model language, if appropriate for the Executive Committee’s consideration. The results revealed that within the professional literature, “White bagging” and “Brown bagging” are defined as follows: White Bagging – refers to the distribution of patient-specific medication from a pharmacy, typically a specialty pharmacy, to the physician’s office, hospital, or clinic for administration...it is often used in oncology practices to obtain costly injectable or infusible medications that are distributed by specialty pharmacies and may not be available in all non-specialty pharmacies. Brown Bagging refers to the dispensing of a medication from a pharmacy (typically a specialty pharmacy) directly to a patient, who then transports the medication(s) to the physician’s office for administration.

Recommendations:

1. The practice of dispensing a specialty drug directly to the patient, who then transports the specialty drug to the physician’s office or clinic, colloquially referred to as “brown bagging,” is determined to be included in the definition of the practice of pharmacy. As such there is no need to define this concept separately in the Model Act. All the conditions and requirements applicable to the practice of pharmacy, including but not limited to, the performance of a drug utilization review, responsibility for the integrity of the medication, patient counseling and education, and the provision of disposal instructions, are applicable to specialty drugs dispensed directly to the patient for subsequent administration by the physician.

2. The study also determined that there is a legitimate patient protection issue when a specialty drug is distributed to an entity other than the patient. The pharmacy distributing the specialty drug is responsible for appropriate notification to the dispensing pharmacy or to patient's agent if the specialty drug is to be administered by the agent.

Out-of-state Pharmacists Providing Medication Order Entry and Review Services

Dr. Ma led the discussion on the following email inquiry:

PipelineRx has our first client in Hawaii for our medication order entry and review service. PipelineRx does not handle drugs of any kind.

Last we spoke you let me know that if we use Hawaii licensed pharmacist they could work from private resident HIPAA compliant offices and PipelineRx would not need a Hawaii license.

Here is my question:

If PipelineRx gets a Hawaii license for one of our resident pharmacies and the pharmacist works from the licensed facility I understand they are not required to have a Hawaii license.

If we get the pharmacy licensed can our pharmacist work from a private resident HIPAA compliant office without having a Hawaii pharmacist license?

After careful consideration, it was the consensus of the Board that:

1. If an out-of-state pharmacy holds a Hawaii miscellaneous permit, pharmacists working out of that pharmacy may perform remote order entry as this is considered under the definition of "Practice of pharmacy" as defined in HRS 461-1 without holding individual Hawaii pharmacists license(s);
2. If an out-of-state pharmacist working in a location that does not have a Hawaii miscellaneous permit wishes to perform remote order entry but NOT dispense any drugs into this State, then the individual pharmacist shall be licensed as a Hawaii pharmacist; and
3. If an out-of-state pharmacist working in a location that does not have a Hawaii miscellaneous permit but is employed by an out-of-state pharmacy that holds a Hawaii miscellaneous permit but the pharmacist practices outside of the permitted/licensed pharmacy by providing remote order entry from his/her home or another office or location and does NOT dispense any drugs into this State, then the individual pharmacist shall be licensed as a Hawaii pharmacist.

In accordance with HAR § 16-201-90, the above interpretation is for informational and explanatory purposes only and based solely on the information provided. It is not an official opinion or decision and therefore not binding on the Board.

Prescriptive Authority for Adult Vaccines, i.e. shingles vaccine

The Vice Chair led the discussion on the following email inquiry from Brian Ziembra, PharmD:

Good afternoon. I am inquiring about the new shingles vaccine (Shingrix) and confirming whether state protocol allows pharmacists to vaccinate for adults ages 50 and older?

Also, I wanted to confirm if pharmacists have prescriptive authority with vaccines or it falls under a supervising physician protocol?

After careful consideration, it was the consensus of the Board that: the Hawaii pharmacy laws and rules permit pharmacists to administer a “vaccine” to anyone 18 years or older pursuant to HRS §461-1, under the definition of “Practice of pharmacy” (E) and that Hawaii pharmacists do not have prescriptive authority except for contraceptive supplies pursuant to § 461-11-6.

In accordance with HAR § 16-201-90, the above interpretation is for informational and explanatory purposes only and based solely on the information provided. It is not an official opinion or decision and therefore not binding on the Board.

Inquiry and Concerns Regarding Insulin and Syringes (Needles) from Katie Hancock, DVM

The Chair led the discussion on the following email inquiry:

I’m a local veterinarian practicing on Oahu.

I’m writing to inquire about what the rules are in Hawaii for insulin dispensing. I’ve had a few pharmacists tell me the needles are prescription and the insulin is over the counter. Recently, a pharmacy replied that they were both over the counter.

What are the current guidelines for insulin (specifically humulin n and glargine) in the state?

I find the lack of any prescription for at least the needles to be alarming. With no written prescription on the pieces- owners with newly diagnosed diabetic pets are expected to order/find the correct insulin type, and correct type and size of syringe. They certainly will have written instructions from our clinic for dosing but the individual components they pick up are unlabeled in this case.

Unlike in people where you can respond appropriately if you start to feel unwell after a dose of insulin- our veterinary patients require a human to be present to witness changes and transport the patient to a clinic. An overdose can have serious medical consequences and even be a fatal occurrence if the pet is unobserved during the day.

After careful consideration, it was the consensus of the Board that:

1. Although insulin needle/syringes are considered OTC and do not require a prescription in order to be sold or dispensed, a practitioner may still write a prescription for this; and
2. The Board of Pharmacy is NOT the authority that determines what drugs or devices require a prescription, but the FDA.

Out-of-state Pharmacy Requirements for dispensing Prescription and/or Diabetic Supplies Into This State

Ms. Keefe led the discussion on the following email inquiry:

I am a pharmacy student rotating with the CVS Caremark pharmacy audit department and I am writing to ask whether it is required for pharmacies to obtain a non-residential license for shipping prescriptions and/or diabetic supplies. The diabetic supplies are being sold and filled pursuant to a prescription written by a physician and the claims could potentially be billed to Medicare, Medicaid, or other government payers. If it is required, could you also send me related information/links (Okay if not)? I really appreciate your help.

After careful consideration, it was the consensus of the Board to respond to the email inquiry as follows:

A pharmacy license/permit is required for any pharmacy (in-state or out-of-state) to “dispense” a prescription device directly to the patient, except if the entity is a durable medical equipment provider and the device that they are “dispensing” does not contain any prescription drugs, then the entity may be required to be licensed by the State Department of Health as a DMEPOS.

In accordance with HAR § 16-201-90, the above interpretation is for informational and explanatory purposes only and based solely on the information provided. It is not an official opinion or decision and therefore not binding on the Board.

Reporting Requirements for Wholesale Prescription Drug Distributors

Dr. Chock led the discussion on the following email inquiry:

April 16 email:

I periodically review internal policies to ensure a wholesaler remains compliant with Hawaii law. Could you confirm that the following information is still correct regarding reporting requirements for wholesalers in Hawaii?

- 1) Suspicious Order (CS) - Not required.
- 2) Suspicious Orders (PSE) - Yes
 - Reports must be made orally to the Department of Public Safety, Narcotics Enforcement Division, whenever possible, at the earliest practicable opportunity after the regulated person becomes aware of the circumstances involved and as much in advance of the conclusion of the transaction as possible. A written report must also be submitted to the Department following an oral report, but the timing is not specified. (Should this be submitted by MAIL?) Haw. Rev. Stat. Ann. § 329-63 (d).
- 3) Transactions (CS) - Not required.
- 4) Transactions (PSE) - Yes.

- Timing of report not specified.
- For PSE: Report the following on a Department-provided form: (i) the generic or other name; (ii) the quantity sold; (iii) the date of sale; (iv) the name and address of the wholesaler; and (v) the name and address of the retailer. Department of Public Safety, Narcotics Enforcement Division- 3375 Koapaka Street, Suite D-100, Honolulu, Hawaii 96819.
Phone: 837-8470
Fax: 837-8474
E-mail: hawaiiicsreg@ned.hawaii.gov (What is the preferred method of communication with the Department?)

After careful consideration, it was the consensus of the Board to refer this inquiry to the Department of Public Safety, Narcotics Enforcement Division as it relates to the reporting of suspicious orders of controlled substances and pseudoephedrine products.

Chapter 91, HRS
Adjudicatory Matters

The Chair called for a recess of the meeting at 9:24 a.m. to discuss and deliberate on the following adjudicatory matter(s) pursuant to Chapter 91, HRS:

In the Matter of the Pharmacist's License of **Daniel K. Loo; PHA 2015-6-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board's Final Order.

Upon a motion by Dr. Chock, seconded by Mr. Weinberg, it was voted on with the Chair, Vice Chair, Dr. Chock, Ms. Keefe and Mr. Weinberg voting yes and Dr. Ma voting no. The motion carried to approve the Board's Final Order for **PHA-2014-12-L**.

Dr. Ma also wanted to invite a representative from RICO explain the process of Settlement Agreements as opposed to going through a formal hearing process.

In the Matter of the Pharmacy License of **Queen's Development Corp. dba Queen's POB I Pharmacy, PHA 2015-111-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board's Final Order.

Upon a motion by Dr. Chock, seconded by Ms. Keefe, it was voted on and unanimously carried to approve the Board's Final Order for **PHA-2014-12-L**.

Following the Board's review, deliberation, and decision in this matter, pursuant to Chapter 91, HRS, the Chair announced that the Board was reconvening its scheduled meeting at 10:43 a.m.

Executive Session:

At 10:43 a.m., upon a motion by Ms. Keefe, seconded by Dr. Ma, it was voted on and unanimously carried to move into executive session pursuant to §92-4 and §92-5(a)(1) and (4), HRS, "To consider and evaluate personal information relating to individuals applying for professional or vocational licenses cited in section 26-9 or both;" and "To consult with the Board's attorney on questions and issues pertaining to the board's powers, duties, privileges, immunities, and liabilities".

PHARMACIST RATIFICATION LIST MAY 17, 2018

PH 4292 SINJIN H <TAKAHASHI<
PH 4293 HOA THI <VO<
PH 4294 CHLOE P <PARRA<
PH 4295 JANICE E <BIERNACKE<
PH 4296 LUCILLE S <BODE<

PHARMACY RATIFICATION LIST MAY 17, 2018

PHY 920 98-1005 MOANALUA RD STE 4000 AIEA HI 96701 PALI MOMI
MEDICAL CENTER

PHARMACY MISCELLANEOUS PERMIT RATIFICATION LIST MAY 17, 2018

PMP 1464 4402 5TH AVE BROOKLYN NY 11220 VLS PHARMACY INC
PMP 1465 711 E CAREFREE HWY STE 140 PHOENIX AZ 85085 ROADRUNNER
PHARMACY INC
PMP 1466 1771 W DIEHL RD #300 NAPERVILLE IL 60563 RXREMOTE
SOLUTIONS
PMP 1467 15271 SOUTHWEST FREEWAY SUGAR LAND TX 77478 BRILLIANT
PHARMACY INC
PMP 1468 2919 WEST SWANN AVE STE 101 TAMPA FL 33609 TAMPA FAMILY
PHARMACY
PMP 1469 1950 SAND LAKE RD BLDG 5 ORLANDO FL 32809 PULBIX SUPER
MARKETS INC PUBLIX PHARMACY #3213
PMP 1470 3502 US HIGHWAY 9 HOWELL NJ 07731 PARKWAY PHARMACY LP
PMP 1471 7413 MIAMI LAKES DR MIAMI LAKES FL 33014 PHARMACY CARE
CENTER LLC
PMP 1472 31818 US 19 N PALM HARBOR FL 34684 PROMISE PHARMACY L L
C
PMP 1473 2401 HASSELL RD STE 1525 HOFFMAN ESTATES IL 60169
PREMIER SPECIALTY INFUSION LLC
PMP 1474 676 S UNIVERSITY BLVD MOBILE AL 36609 PMOA INC
PMP 1475 5408 PARK AVE WEST NEW YORK NJ 07093 LIFELINE RX LLC
PMP 1476 8751 W CHARLESTON BLVD #120 LAS VEGAS NV 89117 ONE WAY
DRUG LLC
PMP 1477 20005 KATY FREEWAY KATY TX 77450 KATY PHARMACY INC
PMP 1478 1324 W WINTON AVE HAYWARD CA 94545 SOLEO HEALTH INC
PMP 1479 381 VAN NESS AVE #1507 & 1508 TORRANCE CA 90501
NUBRATORI INC
PMP 1480 9 CREEK PARKWAY BOOTHWYN PA 19061 PENTEC HEALTH INC
PMP 1481 212 CARPENTERS UNION WAY #500 LAS VEGAS NV 89119 LEVEL
CARE PHARMACY I LLC

**BOARD OF PHARMACY
May 2018 Ratification List**

Miscellaneous Permits (PMP)

Change of PIC

Kaiser Foundation Health Plan Inc.

dba Kaiser Permanente Pharmacy #329 (PMP-1396)

4131 Geary Blvd. FL-1

San Francisco, CA. 94118

New PIC: Johnny Chau

Effective: 11/8/17

RSVP Pharmacy #7 LLC dba RSVP Pharmacy #700 (PMP-1257)

7904 NE Loop 820 Ste A & B

North Richland Hills, TX. 76180

New PIC: Jonathan Nguyen

Effective: 11/27/17

Biologics, Inc. (PMP – 1441)

11800 Weston Pkwy

Cary, NC 27513

New PIC: Phyllis Smith

Effective: 11/22/17

Lake City Pharmacy, LLC (PMP 1446)

33389 Van Dyke

Sterling Heights, MI 48312

New PIC: Kelsey Maki

Effective 11/27/17

ARJ Infusion Services, Inc. (PMP 1139)

7930 Marshall Drive

Lenexa, KS 66214

New PIC: Marjorie Hunt

Effective: 12/8/17

Physician Choice Pharmacy LLC (PMP 818)

4529 North Pine Island Road

Sunrise, FL 33351

New PIC: Brandee Lam

Effective: 4/5/18

Specialty Therapeutic Care LP (PMP 564)

1311 W Sam Houston Pkwy, Ste,150

Houston, TX 77043

New PIC: Kenneth Barnes

Effective: 1/22/18

Kohl's Pharmacy & Homecare Inc. (PMP 538)
dba Essential Pharmacy Compounding
620 N 114th Street
Omaha, NE 68154
New PIC: John T. Houlton
Effective: 2/2/18

Specialty Chemist Corp (PMP 1327)
6560 Fresh Meadows Lane,
Fresh Meadows, NY 11365
New PIC: Kazi Fahmida Islam
Effective: 2/27/18

Pro Care Pharmacy Direct Inc. (PMP 195)
dba CVS/Specialty
105 Mall Blvd.
Monroeville, PA 15146
New PIC: Michelle Byrne
Effective: 11/22/17

Covance Specialty Pharmacy LLC (PMP 605)
100 Technology Park, Ste. 158
Lake Mary, FL 32746
New PIC: Nicole Stinner
Effective: 1/19/18

Procure Pharmacy Care LLC (PMP 1264)
dba Procure Rx
7660 S. Dean Martin Drive, Ste. 203
Las Vegas, NV 89139
New PIC: Michael B. Bitar
Effective: 10/31/17

Prime Therapeutics Specialty Pharmacy LLC (PMP 1407)
dba Prime Therapeutics
2901 Kinwest Pkwy, Ste. 250
Irving, TX 75063
New PIC: Christopher Jurma
Effective: 2/9/18

Park Medical Pharmacy (PMP 1292)
dba Community Medical Center Pharmacy
610 Gateway Center Way #A-E
San Diego, CA 92102
New PIC: Philipe Picart
Effective: 1/15/18

WellDyneRx LLC (PMP 609)
dba WellDyneRx FL
500 Eagles Landing Drive
Lakeland, FL 33810
New PIC: Joseph Fleischman
Effective: 1/15/18

FFP LLC (PMP 784)
dba Matrix Health
3300 Corporate Ave., Ste. 104
Weston, FL 33331
New PIC: Natalie M. Dreyer
Effective: 1/15/18

ESI Mail Pharmacy Service Inc. (PMP 298)
dba Express Scripts
7909 South Hardy Drive, Ste. 106
Tempe, AZ 85284
New PIC: Kathryn Ruetz
Effective: 1/14/18

Accurate Rx Pharmacy Consulting LLC (PMP 1435)
dba Accurate Rx Pharmacy
103-B Corporate Lake Drive
Columbia, MO 65203
New PIC: Kirsten Moloney
Effective: 12/29/17

Village & Compounding Inc. (PMP 1088)
dba Science Pharmaceutical
7225 Fulton Avenue, Ste. H
North Hollywood, CA 91605
New PIC: Golnaz Kamali
Effective: 4/2/18

Option Care Enterprises, Inc. (PMP 1317)
dba Option Care
2050 S Finley Road, #20
Lombard, IL 60148
New PIC: Amy S. Johnson
Effective: 5/2/18

Acro Pharmaceutical Services LLC (PMP 626)
313 Henderson Drive
Sharon Hill, PA 19074
New PIC: Damon Albert
Effective: 4/30/18

Nudak Ventures LLC (PMP 998)
dba Nucara Pharmacy #1
1150 5th Street
Coralville, IA 52241
New PIC: Robbie Schwenker
Effective: 11/30/17

Longs Drug Stores California LLC (PMP 742)
dba Longs Drugs #9954
2470 S. King Street
Honolulu, Hawaii 96826
New PIC: Lauryn Furumoto
Effective: 4/30/17

Name/Trade Name Change
Wedgewood Village Pharmacy LLC (PMP-407)
405 Heron Dr. #200
Swedesboro, NJ. 08085
Effective: 11/13/17

Pharmacy (PHY)

Change of PIC
Longs Drug Stores California LLC dba Longs Drugs #9220 (PHY-718)
4211 Waiialae Ave.
Honolulu, HI. 96816
New PIC: Jamie Mizusawa
Effective: 11/6/17

The Queens Medical Center Pharmacy (PHY-59)
1301 Punchbowl St.
Honolulu, HI. 96813
New PIC: Marcy Matsukawa Rapp
Effective: 11/27/17

Sutter Health Pacific (PHY 561)
dba Kahi Mohala
91-2301 Fort Weaver Road
Ewa Beach, HI 96706
New PIC: Gracie Brooks
Effective: 1/30/2018

Closure/Cancellation PHY & PMP & PWD
Open Door Rx Inc. (PHY-830)
1130 N Nimitz Hwy. Ste. A153 A/B
Honolulu, HI. 96817
Effective: 9/18/17

Open Door Pharmacy LLC dba Open Door Pharmacy (PHY-910)

1130 N Nimitz Hwy. #A153

Honolulu, HI. 96818

Effective: 9/18/17

IAOMAI 4, LLC, dba Lifeway Pharmacy (Koloa) (PHY 806)

5330 Koloa Road, Ste. 2

Koloa, Hawaii 96756

Effective: 4/17/18

RSVP Pharmacy #7, LLC, dba RSVP Pharmacy #701 (PMP 1258)

5004 Frankford Avenue, Se. 119

Lubbock, TX 79424

Effective: 3/19/11

Optimum Health Pharmacy LLC (PMP 1333)

2920 Lithia Pinecrest Road, #D

Valrico, Florida 33596

Effective: 3/23/18

Specialty Chemist Corp. (PMP 1327)

6560 Fresh Meadows Lane

Fresh Meadows, NY 11365

Effective: 4/6/18

Breywell Pharmacy (PMP 1113)

10672 Riverside Drive

North Hollywood, CA 91602

Effective: 4/16/18

Desai Drugs, Inc. (PMP 1341)

dba Guardian Pharmacy

1823 Commercecenter West

San Bernadino, CA 92408

Effective: 4/24/18

Apothecary by Design Acquisition Co. LLC (PMP 1272)

dba Apothecary by Design

141 Preble Street

Portland, ME 04101

Effective: 1/6/18